Overview

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.